NovoSeven RT
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- NovoSeven RT
- Generic name
- COAGULATION FACTOR VIIA (RECOMBINANT)
- Manufacturer
- Novo Nordisk
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- ea65c32f-8518-4383-b621-17056c0eebc0
- SPL ID
- eeebef79-2f60-467f-b01f-58a34f0a8175
- Version
- 21
- Effective date
- 2020-07-10
- Source export date
- 2026-11-13
- Source partition
- 6
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:20:52
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 103665 | derived:openfda.application_number |
| application number | BLA103665 | openfda.application_number | |
| brand name | NovoSeven RT | openfda.brand_name | |
| generic name | COAGULATION FACTOR VIIA (RECOMBINANT) | openfda.generic_name | |
| manufacturer name | Novo Nordisk | openfda.manufacturer_name | |
| ndc | package | 0169-7011-98 | openfda.package_ndc |
| ndc | package | 0169-7218-11 | openfda.package_ndc |
| ndc | package | 0169-7040-01 | openfda.package_ndc |
| ndc | package | 0169-7050-01 | openfda.package_ndc |
| ndc | package | 0169-7208-01 | openfda.package_ndc |
| ndc | package | 0169-7057-11 | openfda.package_ndc |
| ndc | package | 0169-7018-98 | openfda.package_ndc |
| ndc | package | 0169-7001-98 | openfda.package_ndc |
| ndc | package | 0169-7215-11 | openfda.package_ndc |
| ndc | package | 0169-7017-11 | openfda.package_ndc |
| ndc | package | 0169-7010-01 | openfda.package_ndc |
| ndc | package | 0169-7201-01 | openfda.package_ndc |
| ndc | package | 0169-7202-01 | openfda.package_ndc |
| ndc | package | 0169-7002-98 | openfda.package_ndc |
| ndc | package | 0169-7005-98 | openfda.package_ndc |
| ndc | package | 0169-7015-98 | openfda.package_ndc |
| ndc | package | 0169-7020-01 | openfda.package_ndc |
| ndc | package | 0169-7205-01 | openfda.package_ndc |
| ndc | package | 0169-7212-11 | openfda.package_ndc |
| ndc | package | 0169-7211-11 | openfda.package_ndc |
| ndc | package | 0169-7012-98 | openfda.package_ndc |
| ndc | package | 0169-7004-98 | openfda.package_ndc |
| ndc | package | 0169-7047-11 | openfda.package_ndc |
| ndc | package | 0169-7027-11 | openfda.package_ndc |
| ndc | product | 0169-7020 | openfda.product_ndc |
| ndc | product | 0169-7050 | openfda.product_ndc |
| ndc | product | 0169-7201 | openfda.product_ndc |
| ndc | product | 0169-7205 | openfda.product_ndc |
| ndc | product | 0169-7202 | openfda.product_ndc |
| ndc | product | 0169-7208 | openfda.product_ndc |
| ndc | product | 0169-7040 | openfda.product_ndc |
| ndc | product | 0169-7010 | openfda.product_ndc |
| ndc11 | package | 00169705711 | derived:openfda.package_ndc |
| ndc11 | package | 00169704711 | derived:openfda.package_ndc |
| ndc11 | package | 00169721811 | derived:openfda.package_ndc |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: THROMBOSIS • Serious arterial and venous thrombotic events following administration of NOVOSEVEN RT have been reported. [See Warnings and Precautions ( 5.1 )] • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NOVOSEVEN RT. [See Warnings and Precautions ( 5.1 )] • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis. [See Warnings and Precautions ( 5.1 )] WARNING: THROMBOSIS See full prescribing information for complete boxed warning • Serious arterial and venous thrombotic events following administration of NOVOSEVEN RT have been reported. ( 5.1 ) • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NOVOSEVEN RT • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis. ( 5.1 )
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS • Hypersensitivity reactions, including anaphylaxis, can occur with NOVOSEVEN RT. Discontinue infusion and administer appropriate treatment if symptoms appear ( 5.2 ) • Antibody to FVII may occur in FVII deficient patients. Monitor Factor VII deficient patients for prothrombin time (PT) and FVII coagulant activity, and for antibody formation to NOVOSEVEN RT ( 5.3 ) 5.1 Thrombosis • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance. • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, or patients with a history of cardiac, vascular disease or predisposed to thrombotic events may have an increased risk of developing thrombotic events [See Adverse Reactions ( 6.1 ) and Drug Interactions ( 7 )]. • Monitor patients who receive NOVOSEVEN RT for development of signs or symptoms of activation of the coagulation system or thrombosis. When there is laboratory confirmation of intravascular coagulation or presence of clinical thrombosis, reduce the dose of NOVOSEVEN RT or stop the treatment, depending on the patient's condition. 5.2 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, can occur with NOVOSEVEN RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur. 5.3 Antibody Formation in Factor VII Deficient Patients Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity before and after administration of NOVOSEVEN RT. If the factor VIIa activity fails to reach the expected level, or prothrombin time is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed. 5.4 Laboratory Tests Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis. Assays of prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), and plasma FVII clotting activity (FVII:C), may give different results with different reagents. Treatment with NOVOSEVEN has been shown to produce the following characteristics: PT: As shown below, in patients with hemophilia A/B with inhibitors, the PT shortened to about a 7-second plateau at a FVII:C level of approximately 5 units per mL. For FVII:C levels > 5 units per mL, there is no further change in PT. The clinical relevance of prothrombin time shortening following NOVOSEVEN RT administration is unknown. INR: NOVOSEVEN has demonstrated the ability to normalize INR. However, INR values have not been shown to directly predict bleeding outcomes, nor has it been possible to demonstrate the impact of NOVOSEVEN on bleeding times/volume in models of clinically-induced bleeding in healthy volunteers who had received Warfarin, when laboratory parameters (PT/INR, aPTT, thromboelastogram) have normalized. aPTT: While administration of NOVOSEVEN shortens the prolonged aPTT in hemophilia A/B patients with inhibitors, normalization has usually not been observed in doses shown to induce clinical improvement. Data indicate that clinical improvement was associated with a shortening of aPTT of 15 to 20 seconds. FVIIa:C: FVIIa:C levels were measured two hours after NOVOSEVEN administration of 35 micrograms per kg body weight and 90 micrograms per kg body weight following two days of dosing at two hour intervals. Average steady state levels were 11 and 28 units per mL for the two dose levels, respectively. Graph
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NOVOSEVEN in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia. The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NOVOSEVEN in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-877-668-6777 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug product cannot be directly compared to rates in clinical trials of another drug, and may not reflect rates observed in practice. Adverse reactions outlined below have been reported from clinical trials and data collected in registries. Hemophilia A or B Patients with Inhibitors In two studies for hemophilia A or B patients with inhibitors treated for bleeding episodes (N=298), adverse reactions were reported in ≥2% of the patients that were treated with NOVOSEVEN for 1,939 bleeding episodes (see Table 3 below). Table 3: Adverse Reactions Reported in ≥2% of the 298 Patients with Hemophilia A or B with Inhibitors Body System Reactions # of adverse reactions (n=1,939 treatments) # of patients (n=298 patients) Body as a whole Fever 16 13 Platelets, Bleeding, and Clotting Fibrinogen plasma decreased 10 5 Cardiovascular Hypertension 9 6 Serious adverse reactions included thrombosis, pain, thrombophlebitis deep, pulmonary embolism, decreased therapeutic response, cerebrovascular disorder, angina pectoris, DIC, anaphylactic shock and abnormal hepatic function. The serious adverse reactions of DIC and therapeutic response decreased had a fatal outcome. In two clinical trials evaluating safety and efficacy of NOVOSEVEN administration in the peri-operative setting in hemophilia A or B patients with inhibitors (N=51), the following serious adverse reactions were reported: acute post-operative hemarthrosis (n=1), internal jugular thrombosis adverse reaction (n=1), decreased therapeutic response (n=4). Immunogenicity There have been no confirmed reports of inhibitory antibodies against NOVOSEVEN or FVII in patients with congenital hemophilia A or B with alloantibodies. The incidence of antibody formation is dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to NOVOSEVEN RT with the incidence of antibodies to other products may be misleading. Congenital Factor VII Deficiency Data collected from the compassionate/emergency use programs, the published literature, a pharmacokinetics study, and the Hemophilia and Thrombosis Research Society 2 (HTRS) registry showed that 75 patients with Factor VII deficiency had received NOVOSEVEN: 70 patients for 124 bleeding episodes, surgeries, or prophylaxis; 5 patients in the pharmacokinetics trial. The following adverse reactions were reported: intracranial hypertension (n=1), IgG antibody against rFVIIa and FVII (n=1), localized phlebitis (n=1). Immunogenicity In 75 patients with factor FVII deficiency treated with NOVOSEVEN RT, one patient developed IgG antibody against rFVIIa and FVII. Patients with factor VII deficiency treated with NOVOSEVEN RT should be monitored for factor VII antibodies. The incidence of antibody formation is dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to NOVOSEVEN RT with the incidence of antibodies to other products may be misleading. Acquired Hemophilia Data collected from four compassionate use programs, the HTRS registry, and the published literature showed that 139 patients with acquired hemophilia received NOVOSEVEN for 204 bleeding episodes, surgeries and traumatic injuries. Of these 139 patients, 6 patients experienced 8 serious adverse reactions. Serious adverse reactions included shock (n=1), cerebrovascular accident (n=1) and thromboembolic events (n=6) which included cerebral artery occlusion, cerebral ischemia, angina pectoris, myocardial infarction, pulmonary embolism and deep vein thrombosis. Three of the serious adverse reactions had a fatal outcome. Glanzmann’s Thrombasthenia Data collected from the Glanzmann’s Thrombasthenia Registry (GTR) and the HTRS registry showed that 140 patients with Glanzmann’s thrombasthenia received NOVOSEVEN RT for 518 bleeding episodes, surgeries or traumatic injuries. The following adverse reactions were reported: deep vein thrombosis (n=1), headache (n=2), fever (n=2), nausea (n=1), and dyspnea (n=1). 6.2 Postmarketing Experience Adverse reactions reported during postmarketing period were similar in nature to those observed during clinical trials and include reports of thromboembolic adverse events.
adverse reactions table
<table width="100%"><col width="39%"/><col width="32%"/><col width="29%"/><tbody><tr><td align="center" styleCode="Rrule Botrule Toprule " valign="top"><paragraph><content styleCode="bold">Body System</content></paragraph><paragraph>Reactions</paragraph></td><td align="center" styleCode="Rrule Botrule Toprule " valign="top"><paragraph><content styleCode="bold"># of adverse reactions </content></paragraph><paragraph> (n=1,939 treatments) </paragraph></td><td align="center" styleCode="Botrule Toprule " valign="top"><paragraph><content styleCode="bold"># of patients</content></paragraph><paragraph>(n=298 patients) </paragraph></td></tr><tr><td colspan="3" styleCode="Botrule " valign="top"><paragraph><content styleCode="bold">Body as a whole</content></paragraph></td></tr><tr><td styleCode="Rrule Botrule " valign="top"><paragraph>Fever</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>16</paragraph></td><td align="center" styleCode="Botrule " valign="top"><paragraph>13</paragraph></td></tr><tr><td colspan="3" styleCode="Botrule " valign="top"><paragraph><content styleCode="bold">Platelets, Bleeding, and Clotting</content></paragraph></td></tr><tr><td styleCode="Rrule Botrule " valign="top"><paragraph>Fibrinogen plasma decreased</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>10</paragraph></td><td align="center" styleCode="Botrule " valign="top"><paragraph>5</paragraph></td></tr><tr><td colspan="3" styleCode="Botrule " valign="top"><paragraph><content styleCode="bold">Cardiovascular</content></paragraph></td></tr><tr><td styleCode="Rrule Botrule " valign="top"><paragraph>Hypertension</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>9</paragraph></td><td align="center" styleCode="Botrule " valign="top"><paragraph>6</paragraph></td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.